Department of Pancreatic & Endocrine Surgery, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, Liaoning Province, China.
World J Surg Oncol. 2019 Jan 31;17(1):25. doi: 10.1186/s12957-019-1568-x.
The abnormal expression of activator protein-1(AP-1) has recently been investigated in a variety of tumors. While the relationship between AP-1 and thyroid cancer is poorly studied, our study was to evaluate the protein expression and clinical value of AP-1 in papillary thyroid carcinoma (PTC).
The expression of AP-1 was examined by immunohistochemistry on paraffin-embedded tissues obtained from PTC and correspondent paracancerous tissues of 82 patients.
Compared with paracancerous tissues, AP-1 expression was significantly elevated in PTC tissues and the positive rate was 79.3% (65/82). Our study found a linear trend relationship between the expression of AP-1 and tumor size. However, the differences in AP-1 expression among gender, age, lymph node metastasis, number of lesions, location of the lesion, and extrathyroid invasion are not statistically significant.
The expression of AP-1 plays an important role in the proliferation process of PTC.
近来，激活蛋白-1（AP-1）的异常表达在多种肿瘤中得到了研究。虽然 AP-1 与甲状腺癌的关系研究甚少，但我们的研究旨在评估 AP-1 在甲状腺乳头状癌（PTC）中的蛋白表达及其临床价值。
通过免疫组织化学法检测 82 例 PTC 患者及其相应癌旁组织石蜡包埋组织中 AP-1 的表达。
与癌旁组织相比，AP-1 在 PTC 组织中的表达明显升高，阳性率为 79.3%（65/82）。我们的研究发现，AP-1 的表达与肿瘤大小之间存在线性趋势关系。然而，AP-1 表达在性别、年龄、淋巴结转移、病变数量、病变位置和甲状腺外侵犯等方面的差异无统计学意义。
AP-1 的表达在 PTC 的增殖过程中发挥重要作用。
